The goal of this activity is to increase participants’ knowledge of immune checkpoint inhibitors and improve competence and performance in the safe and effective integration of these agents in the treatment of renal cell carcinoma and urothelial carcinoma.

This information was originally presented at the NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ held in Orlando, Florida, from March 23 - 25, 2017.

This information was originally presented at the NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ held in Orlando, Florida, from March 23 - 25, 2017.

Join Eric Jonasch, MD and Marcia Holloway, APRN NP-C from The University of Texas MD Anderson Cancer Center as they present their expertise on a range of cases pertaining to kidney cancer.

The goal of this activity is to increase participants’ ability to use immune checkpoint inhibitors for management of individual patients with urothelial cell and renal cell carcinoma to improve clinical outcomes and quality of life.

The goal of this activity is to increase participants’ ability to use immune checkpoint inhibitors for management of individual patients with urothelial cell and renal cell carcinoma to improve clinical outcomes and quality of life.

The advent of targeted therapies has significantly transformed outcomes for patients with renal cell carcinoma (RCC), yet cure remains elusive.

The advent of targeted therapies has significantly transformed outcomes for patients with renal cell carcinoma (RCC), yet cure remains elusive.

The advent of targeted therapies has significantly transformed outcomes for patients with renal cell carcinoma (RCC), yet cure remains elusive.

The advent of targeted therapies has significantly transformed outcomes for patients with renal cell carcinoma (RCC).